Avanos Medical, Inc.

NYSE:AVNS

Medical - Devices

Healthcare
$24.99 +0.22%

+$0.06 today

Market cap
$1.17B
Beta
1.57
P/E (TTM)
-16.7
EPS (TTM)
-$1.50
52W Low $9.30High $25.49

Volume 0.43M

Average 1.49M

AVNS Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Avanos Medical, Inc.NYSE: AVNS

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $3.7M fell 2.6% year over year, ahead of the -10.7% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 208.3% from the prior quarter. Over 3 fiscal years it compounded at -7.5% a year.

Context

  • Stock-based compensation amounted to 1.8% of revenue in FY2025, down 0.2 pp from a year earlier.
  • Stock-based compensation increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -2.6% holds above the trailing-twelve-month pace of -10.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.7M+208.3% QoQ
Last fiscal yearDec 2025
$12.6M-8.7% YoY
LTMMar 2026
$12.5M-10.7% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.6%——
1 year-8.7%——
3-year CAGR-7.5%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
12.6M USD
Year-over-year change
-8.7%
4-year CAGR
-1.2%

Stock-Based Compensation vs competitors

How AVNS compares with its peers on the latest reported figures

  • AVNS's LTM Mar 2026 stock-based compensation of $12.5M is the 6th largest of the 11 companies compared; the peer median is $12.21M.
  • Its year-over-year change of -10.7% is the 5th highest of 10, against a peer median of -18.0%.
  • Stock-based compensation amounts to 1.7% of revenue for AVNS, versus a peer median of 8.6%.
AVNS Competitors Peer median
Stock-Based Compensation for AVNS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LABStandard BioTools Inc.LTM Mar 2026$27.48M -5.7%+25.8%31.9%
CTKBCytek Biosciences, Inc.LTM Mar 2026$22.82M -18.0%+14.0%11.2%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$19.48M -28.2%+8.7%22.1%
CBLLCeriBell, Inc.LTM Mar 2026$13.6M +94.2%+15.5%14.3%
BVSBioventus Inc.LTM Mar 2026$13.52M +36.9%-10.3%2.3%
AVNSAvanos Medical, Inc.LTM Mar 2026$12.5M -10.7%-7.5%1.7%
VREXVarex Imaging CorporationLTM Apr 2026$10.9M -28.8%+2.3%1.3%
PACBPacific Biosciences of California, Inc.LTM Mar 2026$9.59M -84.2%-19.1%6.0%
CLPTClearPoint Neuro, Inc.LTM Mar 2026$8.49M +16.1%+25.6%20.9%
CYHCommunity Health Systems, Inc.LTM Mar 2026$3M ——0.0%
BCYCBicycle Therapeutics plcLTM Mar 2026$2.68M -107.0%+13.8%4.2%
Peer median (excluding AVNS) $12.21M-18.0%+13.8%8.6%

Competitors are the stored peer set for AVNS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income5.2M50.5M(61.8M)(392.1M)(72.9M)
Depreciation & Amortization38.3M47.7M46.1M45.5M38.9M
Deferred Income Tax(3.4M)0000
Stock-Based Compensation13.2M15.9M15.8M13.8M12.6M
Change in Working Capital26M(24.3M)(18M)35M9.8M
Accounts Receivables(10.8M)(24.7M)39M(6.6M)30.9M
Inventory17.2M(30.9M)4.7M39M200K
Accounts Payables(11.9M)35.4M(14.4M)(900K)600K
Other Working Capital31.5M(4.1M)(47.3M)3.5M(21.9M)
Other Non-Cash Items8M1.1M50.3M398.5M86.3M
Operating Cash Flow87.3M90.9M32.4M100.7M74.7M
Capital Expenditures(21M)(19.3M)(17.8M)(17.8M)(31.6M)
Acquisitions (Net)0(116.1M)39.4M(9.7M)(28M)
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0000(1M)
Investing Cash Flow(21M)(135.4M)21.6M(27.5M)(60.6M)
Debt Repayment(50M)103.4M(64.7M)(33.6M)(34.4M)
Common Stock Issued0000700K
Common Stock Repurchased(11.5M)(45.5M)(19.1M)(12.8M)(3.3M)
Dividends Paid00000
Other Financing Activities6.2M(1.2M)(10.4M)(2.7M)0
Financing Cash Flow(55.3M)56.7M(94.2M)(49.1M)(37M)
Effect of Forex Changes(4M)(3M)200K(4.1M)5M
Net Change in Cash7M9.2M(40M)20M(17.9M)
Free Cash Flow66.3M71.6M14.6M82.9M43.1M

Avanos Medical, Inc.

NYSE:AVNS

Intrinsic Alpha fair value

Locked

Current Price

$24.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.